Personalized Migraine Treatment with Ubrogepant

The present inventive concept discloses novel methods and compositions for the acute treatment of migraine, addressing the limitations of existing treatments by incorporating genetic testing, personalized dosing, and bioavailability enhancers to improve efficacy and safety.

The original patent disclosed methods for treating migraine using ubrogepant, but it did not address the variability in patient response due to genetic differences. The present inventive concept solves this problem by incorporating genetic testing to determine a patient's CGRP receptor sensitivity, allowing for personalized dosing and reducing the risk of adverse effects.

The inventive concept comprises a genetic testing module to determine a patient's genetic predisposition to CGRP receptor sensitivity. Based on the test results, a dosing module calculates a personalized dose of ubrogepant. The pharmaceutical composition may include a bioavailability enhancer, such as cyclodextrins, lipids, or surfactants, to improve the absorption of ubrogepant. Additionally, the inventive concept includes methods for rapid migraine pain relief using fast-dissolving excipients and reducing the risk of CGRP receptor antagonist-associated adverse effects by combining ubrogepant with a gastrointestinal protective agent.

The present inventive concept is novel and non-obvious in its incorporation of genetic testing and personalized dosing, which addresses the variability in patient response and reduces the risk of adverse effects. The use of bioavailability enhancers and fast-dissolving excipients further improves the efficacy and safety of the treatment.

Alternative embodiments of the inventive concept may include using different genetic testing methods, such as whole-genome sequencing or gene expression analysis. The pharmaceutical composition may also include other active ingredients, such as anti-inflammatory agents, to enhance the treatment's efficacy. Additionally, the inventive concept may be adapted for use in other conditions, such as cluster headaches or fibromyalgia, where CGRP receptor antagonists have shown promise.

The present inventive concept has significant commercial potential in the treatment of migraine, a market estimated to reach $8.7 billion by 2025. The personalized approach and improved efficacy and safety profile of the inventive concept are likely to appeal to patients and healthcare providers, offering a competitive advantage over existing treatments.